BioArctic AB (publ)
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, … Read more
BioArctic AB (publ) (BRCTF) - Net Assets
Latest net assets as of September 2025: $1.97 Billion USD
Based on the latest financial reports, BioArctic AB (publ) (BRCTF) has net assets worth $1.97 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.60 Billion) and total liabilities ($627.46 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.97 Billion |
| % of Total Assets | 75.88% |
| Annual Growth Rate | 26.44% |
| 5-Year Change | -1.36% |
| 10-Year Change | N/A |
| Growth Volatility | 298.52 |
BioArctic AB (publ) - Net Assets Trend (2015–2024)
This chart illustrates how BioArctic AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BioArctic AB (publ) (2015–2024)
The table below shows the annual net assets of BioArctic AB (publ) from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $894.94 Million | -14.49% |
| 2023-12-31 | $1.05 Billion | +33.11% |
| 2022-12-31 | $786.24 Million | -0.31% |
| 2021-12-31 | $788.68 Million | -13.07% |
| 2020-12-31 | $907.30 Million | -6.90% |
| 2019-12-31 | $974.50 Million | -4.25% |
| 2018-12-31 | $1.02 Billion | +59.99% |
| 2017-12-31 | $636.13 Million | +946.96% |
| 2016-12-31 | $60.76 Million | -43.89% |
| 2015-12-31 | $108.28 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to BioArctic AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 184.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $305.11 Million | 34.09% |
| Common Stock | $1.77 Million | 0.20% |
| Other Comprehensive Income | $958.00K | 0.11% |
| Other Components | $587.10 Million | 65.60% |
| Total Equity | $894.94 Million | 100.00% |
BioArctic AB (publ) Competitors by Market Cap
The table below lists competitors of BioArctic AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Terveystalo Oy
HE:TTALO
|
$1.01 Billion |
|
Feng Tay Enterprises Co Ltd
TW:9910
|
$1.01 Billion |
|
Guangdong Meiyan Jixiang Hydropower Co Ltd
SHG:600868
|
$1.01 Billion |
|
Chongqing Chuanyi Automation Co Ltd
SHG:603100
|
$1.01 Billion |
|
3M India Limited
NSE:3MINDIA
|
$1.01 Billion |
|
WT Microelectronics Co. Ltd. Pfd.
TW:3036A
|
$1.01 Billion |
|
Yinson Holdings Bhd
KLSE:7293
|
$1.01 Billion |
|
Guangdong Topstar Technology Co Ltd
SHE:300607
|
$1.01 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioArctic AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,046,575,000 to 894,942,000, a change of -151,633,000 (-14.5%).
- Net loss of 177,079,000 reduced equity.
- New share issuances of 6,016,000 increased equity.
- Other factors increased equity by 19,430,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-177.08 Million | -19.79% |
| Share Issuances | $6.02 Million | +0.67% |
| Other Changes | $19.43 Million | +2.17% |
| Total Change | $- | -14.49% |
Book Value vs Market Value Analysis
This analysis compares BioArctic AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.79x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 10.54x to 1.79x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $1.72 | $18.10 | x |
| 2016-12-31 | $0.69 | $18.10 | x |
| 2017-12-31 | $7.22 | $18.10 | x |
| 2018-12-31 | $11.56 | $18.10 | x |
| 2019-12-31 | $11.07 | $18.10 | x |
| 2020-12-31 | $10.30 | $18.10 | x |
| 2021-12-31 | $8.96 | $18.10 | x |
| 2022-12-31 | $8.93 | $18.10 | x |
| 2023-12-31 | $11.83 | $18.10 | x |
| 2024-12-31 | $10.13 | $18.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioArctic AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.79%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -68.81%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 1.24x
- Recent ROE (-19.79%) is below the historical average (12.51%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 3.43% | 8.92% | 0.32x | 1.21x | $-7.12 Million |
| 2016 | 94.77% | 54.52% | 0.15x | 11.65x | $51.50 Million |
| 2017 | 2.38% | 10.77% | 0.12x | 1.79x | $-48.46 Million |
| 2018 | 37.50% | 53.45% | 0.51x | 1.37x | $279.83 Million |
| 2019 | 9.08% | 31.40% | 0.24x | 1.21x | $-8.98 Million |
| 2020 | -7.55% | -109.90% | 0.06x | 1.16x | $-159.25 Million |
| 2021 | -15.19% | -517.54% | 0.03x | 1.14x | $-198.66 Million |
| 2022 | -1.42% | -4.90% | 0.27x | 1.09x | $-89.80 Million |
| 2023 | 21.90% | 37.22% | 0.52x | 1.13x | $124.59 Million |
| 2024 | -19.79% | -68.81% | 0.23x | 1.24x | $-266.57 Million |
Industry Comparison
This section compares BioArctic AB (publ)'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioArctic AB (publ) (BRCTF) | $1.97 Billion | 3.43% | 0.32x | $1.01 Billion |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |